Gyre Therapeutics (GYRE) director discloses no stock ownership

Rhea-AI Filing Summary

Gyre Therapeutics, Inc. reported an initial statement of beneficial ownership for Kirkby Maxwell. He is identified as a director, not an officer or 10% owner, and currently has no reportable securities holdings or transactions. Remarks reference an Exhibit 24 Power of Attorney.

Key Figures

Reported transactions: 0 Reported holding entries: 0 Derivative transactions: 0

3 metrics

Reported transactions 0 Total transactions listed in this initial beneficial ownership statement

Reported holding entries 0 Number of securities holdings reported for Kirkby Maxwell

Derivative transactions 0 Derivative transaction count in the insider ownership data

Key Terms

Power of Attorney, reporting persons

2 terms

Power of Attorney regulatory

"Remarks note: "Exhibit 24 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

reporting persons regulatory

"Reporting persons include Kirkby Maxwell as a director"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/04/2026 - 08:24 PM Accepted by SEC EDGAR 08/04/2026 - 08:24 PM Learn about SEC filing dates

FAQ

What role does Kirkby Maxwell have at Gyre Therapeutics (GYRE)?

Kirkby Maxwell is identified as a director of Gyre Therapeutics, Inc. He is not listed as an officer and is not classified as a 10% owner, indicating his position is board-level oversight rather than executive management or major shareholder.

Does the GYRE Form 3 show any share ownership for Kirkby Maxwell?

The Form 3 reports no securities holdings for Kirkby Maxwell in Gyre Therapeutics, Inc. It also lists no transactions or derivative positions, indicating there are currently no reportable equity interests attributed to him under insider reporting rules.

Were any insider transactions reported for GYRE in this Form 3?

No insider transactions are reported; all transaction counters are zero. The disclosure functions as an initial statement confirming that, as of this report, Kirkby Maxwell has no acquisitions, dispositions, or exercises of Gyre Therapeutics, Inc. securities to disclose.

Is Kirkby Maxwell identified as a ten percent owner of GYRE stock?

Kirkby Maxwell is not identified as a ten percent owner of Gyre Therapeutics, Inc. The ownership classification indicates he serves solely as a director, without a disclosed equity stake large enough to qualify as a major shareholder.

Does the GYRE Form 3 mention any derivative or option positions for Kirkby Maxwell?

The disclosure lists no derivative securities for Kirkby Maxwell. Derivative-related counts, including derivative transactions and holding entries, are all zero, indicating there are no reportable options, warrants, or similar instruments associated with him at this time.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kirkby Maxwell

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2026

3. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Thomas Eastling, as attorney-in-fact for Maxwell Kirkby	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)